Blue Arbor Technologies has raised $10.2M in seed funding, a round that signals growing investor appetite for advanced medical devices targeting limb loss. The company is developing implantable interfaces designed to read volitional motor signals directly from the body, giving prosthetic users more precise and reliable control than traditional surface-based systems.
The fresh capital arrives as the field of prosthetic rehabilitation pushes toward more seamless integration between human physiology and machine. Blue Arbor’s approach-implanting sensors to capture neural intent-could address a persistent pain point for amputees: the lag and imprecision that often come with current control methods. While the company hasn’t disclosed who backed the round, the size suggests conviction in the technology’s potential to move beyond early-stage experimentation.
